Top Stories
The PD-L1 inhibitor is cleared for use in patients with muscle-invasive bladder cancer who have molecular residual disease following surgery.
The reported exit of Tracy Beth Høeg could come just days after the resignation of FDA Commissioner Marty Makary, according to Reuters.
Ligufalimab in combination with azacitidine and venetoclax achieved an objective response rate of 80%.
Sales for the Alzheimer's treatment are set to grow by around 63% as subcutaneous auto-injector approval for early disease looms.
The FDA placed a clinical hold on the Phase III HERO trial of ARD-101, while Cabaletta said three patients with pemphigus vulgaris who skipped a preconditioning regimen still achieved B cell depletion.
Conference News
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prosta...
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg DosesPost-dose Biopsies Pro...
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseasesKT...
BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, ...
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) a...
